Upload
dr-zafar-iqbal
View
317
Download
2
Embed Size (px)
Citation preview
Dr Zafar Iqbal
M.Phil., Ph.D., Postdoctorate
Assistant Professor (Medical Genetics /Hematology & Oncology)
King Saud Bin Abdulaziz University for Health Sciences
King Abdulaziz Medical City, National Guard Health Affairs
Riyadh 11426, Saudi Arabia.
Phone: +966-53-86-355-86 / -11-42-95320
E-mail: [email protected] / [email protected]
Academic Qualifications:
1) Fellowship (Medical Genomics / Clinical Hematology) 2007-2008
Shanghai Institute of Hematology, Rui-Jin Hospital, Shanghai Jiao-Tong University School of Medicine (SJTU), China
(Post-doctoral fellowship in Functional Medical Genomics / Clinical Hematology)
2) Ph.D. * (Molecular Genetics / Hematology & Oncology) 2001-2007
SJTU China & University of the Punjab, Lahore, Pakistan.
3) M.Phil. (MS) (Molecular Biology / Biomedical sciences) 1999-2001
Centre of Excellence in Molecular Biology, University of the Punjab, Lahore.
*PhD work was carried out at SJTU School of Medicine Shanghai China, University of Tokyo Hospital Japan and National Institute for Biotechnology & Genetic Engineering (NIBGE), Faisalabad, Pakistan, and degree was awarded by University of the Punjab Lahore Pakistan.
Page 1 of 31
List of Publications
Full-text Articles (37):
1. Iqbal Z, Mahmood R, Aleem A. Status of BCR-ABL monitoring in developing
countries and need for careful application for automated Xpert BCR-ABL Monitor™
(Cepheid) system in CML patients: Saudi Arabia as an example. Blood (Online),
12/2015; 126(3):5170 E-Letter. 10.45 Impact Factor.
http://www.bloodjournal.org/content/126/23/5170.e-letters.
2. Rasool M, Iqbal Z, Israr S, Saleem S, Gillani Z, Qazi MH, et al. . BAD, a
Proapoptotic Protein, Escapes ERK/RSK Phosphorylation in Deguelin and siRNA-
Treated HeLa Cells. PLOS one 2015 December (accepted for publication).
3.23 Impact Factor.
3. Iqbal Z, Khalid K, Akhtar T, Sabir N, Aleem M, Rasool M, et al. High frequency and
poor prognosis of late childhood BCR-ABL positive and MLL-AF4 positive ALL
define the need for advanced molecular diagnostics and improved therapeutic
strategies in pediatric B-ALL in Pakistan. Mol Diagn Ther. 2015 Oct;19(5):277-87.
2.891 Impact Factor
4. Aljamaan K, Aljumah TK, Aloraibi S, Absar M, Iqbal Z. Low Frequency of ETV6-RUNX1 (t
12; 21) in Saudi Arabian Pediatric Acute Lymphoblastic Leukemia Patients: Association with
Clinical Parameters and Early Remission. Asian Pac J Cancer Prev. 2015; 16(17):7523-7.
5. Tahira B, Asif M, Khan S, Hussain A, Shahwani MN, Malik A, Inayatullah S, Iqbal
Z, Rasool M. Detection of BCR/ABL Fusion Gene by Hematological and
Cytogenetical Analysis in Chronic Myeloid Leukemia Patients in Quetta, Pakistan.
Asian Pac J Cancer Prev. 2015; 16(9):3793-7. 2.51 Impact Factor
6. Shahid M, Sabar MF, Bano I, Rahman Z, Iqbal Z, Fatim Ali SS, Ghani MU, Iqbal M,
Husnain T. Sequence variants on 17q21 are associated with the susceptibility
of asthma in the population of Lahore, Pakistan. J Asthma. 2015 Jul 23:1-8.
Page 2 of 31
7. Rasool M, Farooq S, Malik A, Shaukat A, Manan A, Asif M, Sani S, Qazi MH, Kamal
MA, Iqbal Z, Hussain A. Assessment of circulating biochemical markers and
antioxidative status in acute lymphoblastic leukemia (ALL) and acute myeloid
leukemia (AML) patients. Saudi J Biol Sci. 2015 Jan; 22(1):106-11.
8. Iqbal Z. Molecular genetic studies on 167 pediatric ALL patients from different areas
of Pakistan confirm a low frequency of the favorable prognosis fusion oncogene TEL-
AML1 (t 12; 21) in underdeveloped countries of the region. Asian Pac J Cancer Prev.
2014; 15(8):3541-6.
9. Tayyab M, Khan M, Akhtar T, Iqbal Z, Noor Z, Noor N. Distinct Gene Mutations,
their Prognostic Relevance and Molecularly Targeted Therapies in Acute Myeloid
Leukemia (AML). J Cancer Sci Ther 2014, 6:337-349. doi: 10.4172/1948-
5956.1000292. http://omicsonline.org/open-access/distinct-gene-mutations-their-
prognostic-relevance-and-molecularly-targeted-therapies-in-acute-myeloid-
leukemia-aml-1948-5956.1000292.pdf
10. Iqbal Z, Akhtar T, Akram AM, Khalid M, Shah IH, Aleem A, et al. Detection
of Compound BCR-ABL Mutations in TKI Resistant CML Patients Including a
Novel K245N Mutation Associated with Primary Nilotinib Resistance By Employing
a Newly Developed Cost Effective BCR-ABL Sequencing Protocol. Blood 2014: 124
(21): 1810. http://www.bloodjournal.org/content/124/21/1810.
11. Iqbal Z. A comprehensive analysis of breakpoint cluster region-abelson fusion
oncogene splice variants in chronic myeloid leukemia and their correlation with
disease biology. Indian J Hum Genet. 2014 Jan; 20(1):64-8.
12. Akram A, Akhtar T and Iqbal Z. Survival assessment and Optimization of
BCR/ABL-KD amplification protocol for detection of Imatinib resistant mutations in
Page 3 of 31
Ph+ Chronic Myeloid Leukemia patients from Pakistan
Gene therapy & molecular biology 02/2014; 16:10. 0.72 Impact Factor
http://www.gtmb.org/volumes/Vol16/2.Akram_et_al_10-29.pdf
13. Aleem A, Shakoor Z, Alsaleh K, Algahtani F, Iqbal Z, Al-Momen A.
Immunological evaluation of β-thalassemia major patients receiving oral iron chelator
deferasirox. J Coll Physicians Surg Pak. 2014 Jul;24(7):467-71.
14. Rasool M, Rashid S, Arooj M… Iqbal Z, Gan SH, Kamal MA, Sheikh IA. New
possibilities in hepatocellular carcinoma treatment. Anticancer Res. 2014 Apr;
34(4):1563-71.
15. Rasool M, Malik A, Qazi A, Sheikh I, Manan A, Shaheen S, Iqbal Z et al.
Current View From Alzheimer Disease To Type 2 Diabetes Mellitus. CNS &
Neurological disorders-Drug Targets 2014 Apr; 13(3):533-42.
16. Shahbaz S, Akhtar T, Iqbal Z. Optimization of nested RT-PCR for the detection
of a common fusion oncogene AML1/ETO of Acute Myeloid Leukemia in Pakistan.
Biologica 2014, 60 (2): 255-260. ISSN 2313 – 206X.
17. Karim S; Ansari SA; Rasool S; Iqbal Z; Sohrab SS; Abuzenadah AM and Al-
Qahtani M. Transcriptomics study of neurodegenerative disease: Emphasis on
synaptic dysfunction mechanism in Alzheimer’s disease. CNS Neurol Disord Drug
Targets. 2014;13(7):1202-12.
18. Alanazi A, Alsalmeh M, Alsomali O, Almurshdi AM, Alabdali A, Al-Sulami
M, Al-Nemer A, Al-Qusairy A, Aloraibi S and Iqbal Z. Poor Basic Life Support
Awareness among Medical and College of Applied Medical Sciences Students
Necessitates the Need for Improvement in Standards of BLS Training and Assessment
for Future Health Care Providers. Middle-East Journal of Scientific Research 21 (5):
Page 4 of 31
848-854, 2014. DOI: 10.5829/idosi.mejsr.2014.21.05.82335
http://www.idosi.org/mejsr/mejsr21%285%2914/21.pdf
19. Alanazi A, Al Moamary M, Ismaeli T, Alanazi AN, Olayan LH, Alanazi AM,
Abu Nurah HY, Iqbal Z and Qureshi S. The Reliability of the Arabic Version of the
Asthma Knowledge Questionnaire and Assessment of the Level of Asthma Awareness
among Parents of Children with Asthma in Saudi Arabia. Middle-East Journal of
Scientific Research 20(4):412-418, 2014. DOI: 10.5829/idosi.mejsr.2014.20.04.82258.
http://www.idosi.org/mejsr/mejsr20%284%2914/2.pdf
20. Iqbal Z , Aleem A, Iqbal M,…, Khalid AM et al. Detection of pre-existing
BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic phase
chronic myeloid leukemia patients is associated with imatinib resistance: First large-
scale study with implication in post-Imatinib era. PLoS ONE 2013; 8(2): e55717.
doi:10.1371/journal.pone.0055717.
21. Aleem A, Anjum F, Algahtani F, Iqbal Z, Alsaleh K. Clofarabine in the
treatment of elderly patients with acute myeloid leukemia. Asian Pac J Cancer Prev.
2013; 14(2):1089-92.
22. Awan T, Iqbal Z, Aleem A, Sabir N, Absar M, Rasool M et al, . Five Most
Common Prognostically Important Fusion Oncogenes are Detected in the Majority of
Pakistani Pediatric Acute Lymphoblastic Leukemia Patients and are Strongly
Associated with Disease Biology and Treatment Outcome. Asian Pac J Cancer Prev.
2012; 13(11):5469-5475.
23. Iqbal Z . Molecular Hematology in Leukemia Biology and Treatment: Past,
present and future. J. App. Hematol. 2012 October; 3(2):55-61.Page 5 of 31
24. Begum M, Karim S, Malik A, Khurshid R, Asif M, Salim A, Nagra SA, Zaheer
A, Iqbal Z, Abuzenadah AM, Alqahtani MH, Rasool M.CA 15-3 (Mucin-1) and
Physiological Characteristics of Breast Cancer from Lahore, Pakistan. Asian Pac J
Cancer Prev. 2012; 13(10):5257-61.
25. Aleem A, Al Diab AR, Alsaleh K, Algahtani F, Alsaeed E, Iqbal Z, El-Sherkawy
MS. Frequency, Clinical Pattern and Outcome of Thrombosis in Cancer Patients.
Asian Pac J Cancer Prev., 2012; 13(4):1311-5.
26. Sabir N, Iqbal Z , Aleem A, Awan T, Naeem T, Asad S, et al. Prognostically
Significant Fusion Oncogenes in Pakistani Patients with Adult Acute Lymphoblastic
Leukemia and Their Association with Disease Biology and Outcome. Asian Pac J
Cancer Prev., 2012;13(7):3349-55..
27. Iqbal Z , Manzoor F, Iqbal M, Ali S, Sheikh N, Khan M; Aleem A , Tanveer A.
Frequency of BCR-ABL Fusion Oncogene Splice Variants Associated with Chronic
Myeloid Leukemia (CML). Journal of Cancer Therapy, 2011, 2, 176-180.
28. Malik S, Hanif A, Khokher S, Iqbal Z, Rana S, Imran M, Bilal M, Arslan M.
Association of genetic and non-genetic risk factors with specific BRCA mutation
positive breast cancers in some Pakistani females. Pak J Physiol 2009;5(1): 51-57.
Page 6 of 31
29. Iqbal Z., Iqbal M. and Akhtar T. Frequency of BCR-ABL fusion oncogene in
Pakistani childhood acute lymphoid leukaemia (ALL) patients reflects ethnic
differences in molecular genetics of ALL.J. Paed. Hemat. Oncol., 2007, 29 (8): 585.
30. Iqbal Z. Siddiqui R.T., Qureshi J. A. and Ahmad M. Khalid. Case study of
primary Imatinib resistance and correlation of BCR-ABL multiple mutations in
chronic myeloid leukemia. Therapy (2004), 1(2): 249-254.
31. Iqbal Z., Siddiqui R.T. and Qureshi J. A. Two different point mutations in BCR-
ABL gene ATP-binding domain conferring primary Imatinib resistance in a chronic
myeloid leukemia (CML) patient: a case report. Biol. Proced. Online 2004; 6(1): 144-
148.
32. Zafar Iqbal , Ijaz Shah, Aamer Aleem, Mubashar Naqvi, Ammara Tahir, et al.
Detection of BCR-ABL kinase domain mutations in CD34+ cells from newly
diagnosed chronic phase CML patients and their association with imatinib resistance.
Nature Precedings Online. 28 November 2011.
http://precedings.nature.com/documents/6645/version/1.
33. Iqbal Z., Siddiqui R. T. and Qureshi J. A. Detection of point mutations
conferring acquired and natural Gleevec resistance in chronic myeloid leukemia
patients. J. Pak. Med. Assoc., December 2003, 53(12): 9-10.
Page 7 of 31
34. Tanveer, A., and Iqbal, Z. 2000. Isolation of Bacillus sp., from water samples
collected from snail habitats and its evaluation as biomolluscicide. Punjab Univ. J.
Zool., 15: 171-181.
35. Iqbal Z., Muqaddas A. and Tanveer A. Evaluation of Bacillus sp. as
biomolluscicide against freshwater snail Lymnaea acuminata. Punj. Univ. J. Zool.,
2000, 9: 50-57.
36. Iqbal Z., Muqaddas A. and Tanveer A. Some studies on bacteria isolated from
freshwater physid snail and their evaluation as snail controlling agent. Acta Scientia,
January 1999, 9: 58-68.
37. Iqbal Z., Muqaddas A. and Tanveer A. Some studies on pathogenic bacteria
isolated from freshwater lymnaid snails and their evaluation as snail controlling agent.
Acta Scientia, January 1999, 9: 69-78.
Abstracts/research reports published in ISI-indexed journals:
38. Iqbal Z, Akram MA · Akhtar T, Khalid M, Zeba A· Aleem A, et al. High
Frequencies of Compound BCR-ABL Mutations and Their Association with Imatinib
Resistant, Disease Progression and Late Chronic Phase Disease in Pakistani Chronic
Myeloid Leukemia Patients Necessitate the Inclusion of Molecular Testing in Routine
Clinical Settings . Blood 12/2015; 126(23):5167. · 10.45 Impact Factor.
https://www.researchgate.net/profile/Zafar_Iqbal53/contributions
Page 8 of 31
39. Aamer A, Al Wusibai F, AlSaleh K, Alqahtani F, Iqbal Z, Chaudhri NA, Al-
Momen AK. Multiple Brain Hemorrhages on Presentation in a Patient with
Accelerated Phase Chronic Myeloid Leukemia and Subsequent CNS Blast Crisis
Despite Systemic Complete Molecular Response: Possible Role of CNS Bleed in
Leukemia Proliferation . Blood 12/2015; 126(23):5153. · 10.45 Impact Factor
40. Aljamaan K, Aljumah TK, Aloraibi S, Absar M, Iqbal Z. Low Representation of
ETV6-RUNX1 Fusion Oncogene in Pediatric Acute Lymphoblastic Leukemia Patients
from Saudi Arabia and Strong Association with Clinical Response to Day-14 of
Remission Induction Therapy . Blood 12/2015; 126(23):4987. · 10.45 Impact Factor
41. Zafar Iqbal, Tashfin Awan, Tanveer Akhtar, Aleem Aamer, Noreen Sabir,
Muhammad Absar, Iqbal Mudassar, Ahmad Mukhtar Khalid, Giuseppe Saglio,
Mahmood Rasool, and Akhtar Hussain. High Frequency Of BCR-ABL/t(22;9)
Translocation As Detected By RT-PCR and Interphase FISH In Pediatric B-Cell ALL
Patients Identifies The Need For Immediate Inclusion Of Tyrosine Kinase Inhibitors
In Pediatric ALL Treatment Protocols. Blood 2013 122:3908.
42. Zafar Iqbal, Saba Shahzadi, Tanveer Akhtar, Aleem Aamer, Ahmad Mukhtar
Khalid, and Iqbal Mudassar. BCR-ABL Splice Variants In Three Phases Of CML:
Association With Disease Biology and Response To Imatinib. Blood 2013 122:5191.
43. Zafar Iqbal , Sabir Noreen, Aleem Aamer, Awan Tashfeen, Tahir Naeem, Asad
Sultan, et al. Characterization of Common Fusion Oncogenes As Prognostic
Molecular Identities in Adult Acute Lymphoblastic Leukemia Identifies the Need
Page 9 of 31
for Genetic Testing At Presentation, Molecular Prognostication and Differential
Treatment. Blood (ASH Annual Meeting Abstracts) 120 (21): 5115. (Impact Factor
9.90)
44. Zafar Iqbal , Sabir Noreen, Aleem Aamer, Awan Tashfeen, Tahir Naeem, Asad
Sultan, et al. Detection of Five Common Fusion Oncogenes in Pakistani Children with
Acute Lymphoblastic Leukemia and Their Association with Clinical Pattern and
Treatment Outcome. Blood (ASH Annual Meeting Abstracts) 120 (21): 5124. (Impact
Factor 9.90)
45. Zafar Iqbal , Tashfeen Awan, Mudassar Iqbal, Noreen Sabir. High frequency of
BCR-ABL oncogene in pediatric acute lymphoblastic leukemia (ALL) patients as
revealed by RT-PCR and interphase FISH: association with disease biology and
treatment outcome. J Clin Oncol 30, 2012 (suppl): 6612 (Proceedings of 2012 Annual
Meeting of American Society of Clinical Oncology, Chicago, Illinois, USA). (Impact
Factor 18.372)
46. Zafar Iqbal , Mudassar Iqbal, Tanveer Akhtar, Mubashar Iqbal Naqvi, Ammara H
Tahir, Tariq Jameel Gill, et al . Presence of Prior-to-Treatment BCR-ABL Mutations
In CD34+CD38- Stem Cells of Newly Diagnosed Chronic Phase CML Patients and
Their Correlation with Imatinib Resistance: Implications of Cancer
Pharmacogenomics and Pre-Therapeutic Genetic Testing In Personalized Treatment of
Page 10 of 31
BCR-ABL+ Leukemia. Blood (ASH Annual Meeting Abstracts) 116 (21): 2278.
(Impact Factor 9.90)
47. Z Iqbal , N Sabir, M Iqbal, A Tashfeen, A Aleem, A Mukhtar Khalid, T Akhtar.
Poor Outcome Of TCF3-PBX1 Despite Its Association With Favorable Risk Factors
Stresses The Need For Intensified Remission Therapy For Patients Of This Genetic
Subgroup In Adult Acute Lymphoid Leukemia. Haematologica 2013; 98(s1): 264.
EHA Abstract n. P625 (Impact Factor 6.424).
48. Z Iqbal , A Tashfeen, M Iqbal, N Sabir, A Aleem, A Mukhtar Khalid, T Akhtar.
High Frequency of BCR-ABL In Pediatric Acute Lymphoid leukemia with Poor
Outcome Identifies The Immediate Need For Incorporation of Imatinib And Other
Tyrosine Kinase Inhibitors In Treatment Protocols. Haematologica 2013; 98(s1): 268.
EHA Abstract n. P635 (Impact Factor 6.424).
49. Iqbal Z , Li-Juan Z, Baig SM, Aziz Z, Shah IH, Khalid M, Iqbal M and Tanveer
A.. First comprehensive study on pre-existing BCR-ABL KD mutations and
subsequent Imatinib resistance in CML patients: Value of pre-treatment genetic testing
and implication in patient-tailored therapy of Leukaemia. Annals of Oncology, May
2008, 19 (3): 40-41.
50. Iqbal Z., Baig S.M., Aziz Z. and Akhtar T. Clinical significance of pre-existing
BCR-ABL gene ATP-binding domain mutations in chronic myeloid leukemia (CML)
patients: implication in prognosis and Imatinib follow-up studies. Annals of Oncology,
2007, 18(Supp. 4): iv4.
Page 11 of 31
51. Iqbal Z. High frequency of pre-existing BCR-ABL gene ATP-binding domain
mutations associated with natural Gleevec resistance in chronic myeloid leukemia
(CML) patients. Haematologica, 2006; 91(s3): 3.
52. Iqbal Z. Frequency of chromosomal abnormalities and corresponding fusion
oncogenes in acute lymphoblastic leukemia (ALL) patients of Pakistan and its
implication in differential diagnosis and prognosis of leukemia. Haematologica, 2006;
91(s3):65.
53. Iqbal Z. Co-existence of fusion transcripts SIL-TAL1 and BCR-ABL in a
paediatric acute lymphoblastic leukaemia (ALL) patient. Haematologica, 2006;
91(s3):6.
54. Iqbal Z and Tanveer A. Detection of double fusion transcripts/ oncogenes (BCR-
ABL, SIL-TAL1) in childhood acute lymphoblastic leukaemia (ALL). Haematologica,
2006; 91(s3):68.
55. Iqbal Z and Tanveer A. A comprehensive analysis of pre-existing BCR-ABL
gene ATP-binding domain mutations associated with natural Gleevec resistance in
chronic myeloid leukemia (CML) patients. Haematologica, 2006; 91(s3):93.
56. Iqbal Z and Tanveer A. First report of co-existence of double fusion transcripts
(BCR-ABL and E2A-PBX1) in t-cell acute lymphoblastic leukaemia (ALL).
Haematologica, 2006; 91(s3):68.
57. Iqbal Z. Eradication of Imatinib-resistance-conferring, pre-existing BCR-ABL
ATP-binding domain mutant clones by sustained interferon therapy in CML patients.
Haematologica, 2006; 91(s3):97
Page 12 of 31
58. Iqbal Z and Tanveer A. Incidence of different fusion oncogenes in acute
lymphoblastic leukemia (ALL) patients from Pakistan: possible implication in
differential diagnosis, prognosis, treatment and management of ALL. Haematologica,
2006; 91(s3):64.
59. Iqbal Z. Detection of ring chromosome 21 and Philadelphia chromosome (t
9:22) in a chronic phase CML patient and its response to interferon and Imatinib
treatments. Haematologica, 2006; 91(s3):99.
60. Iqbal Z and Baig SM. Optimization of simple PCR assay for detection of Globin
gene deletions in alpha-thalassemia patients. Haematologica, 2006; 91(s3): 136.
61. Iqbal Z. Detection of BCR-ABL ATP-binding domain mutations in Imatinib
resistance CML patient who relapsed after bone marrow transplant. Haematologica,
2006; 91(s3): 139.
62. Iqbal Z, Aziz Z and Tanveer A. Clinical and molecular biological studies on
susceptibility and resistance to Imatinib in Pakistani CML patients: first
comprehensive report from South-East Asia. Haematologica, 2006; 91(s3):98.
Iqbal Z and Tanveer A. High incidence of BCR-ABL fusion oncogene in Pakistani
childhood acute lymphoid leukaemia (ALL) patients reflects ethnic differences in
molecular genetics of ALL. Haematologica, 2006; 91(s3):65.
63. Iqbal Z, Abid Sohail Taj and Tanveer a. Studies on post bone marrow transplant
(post-BMT) Imatinib resistance in a chronic myeloid leukaemia (CML) patient.
Haematologica, 2006; 91(s3): 139.
Page 13 of 31
64. Iqbal Z, Aziz Z, Shah IH and Tanveer A. Interferon therapy prior to Imatinib
can eradicate pre-existing BCR-ABL ATP-binding domain mutations conferring
natural Imatinib resistance in CML patients. Haematologica, 2006; 91(s3):96
65. Iqbal Z, Aziz Z, Shah IH, Khalid M and Tanveer A. First report of ring
chromosome 21 and Philadelphia chromosome (BCR-ABL fusion gene) in a 40 years
old CML patient resistant to Hydroxyurea: response to interferon and Imatinib.
Haematologica, 2006; 91(s3):97.
66. Iqbal Z. Case report of co-existence of double fusion transcripts (BCR-ABL,
E2A-PBX1) in T-cell acute lymphoblastic leukaemia (ALL). Haematologica, 2006;
91(s3):64.
67. Siddiqui R. T., Qureshi J. A. and Iqbal Z. Development of quantitative
competitive reverse transcriptase PCR (QC-RT-PCR) for detection of minimal
residual disease (MRD) and monitoring anti-leukaemic therapy response in
philadelphia chromosome positive leukemia. Haematologica 2004, 89 (suppl.n.6):94.
68. Iqbal Z., Aziz Z., Siddiqui R.T., Qureshi J. A. and Khalid A.M. first report of
multiple point mutations in BCR-ABL gene ATP-binding domain conferring primary
Imatinib resistance in chronic myeloid leukemia patient. Haematologica 2004, 89
(suppl.n.6):97.
Articles presented at prestigious international Conferences (published
as proceedings):
Page 14 of 31
69. Zafar Iqbal; Akhtar Tanveer; Shahid Mahmood Baig; Zeba Aziz; Mudassar
Iqbal; et al. T315I and M351T are the most frequent prior-to-Imatinib BCR-ABL
kinase domain mutations in chronic phase CML patients and lead to natural Imatinib
resistance. In: Online Proceedings of Second AACR (American Association for
Cancer Research)-Dead Sea International Conference on Advances in Cancer
Research: From the Laboratory to the Clinic, March 7-10, 2010, King Hussein Bin
Talal Convention Center, Dead Sea, Jordan.
70. Zafar Iqbal, Akhtar Tanveer, Mudassar Iqbal, Muhammad Ferhan, Shahid M.
Baig, Mubashar Iqbal Naqvi, et al. First comprehensive report of strong interplay of
genetic and environmental factors as well as high degree of ethnic and geographical
variations in biology of Leukemia as manifested by frequencies of common fusion
oncogenes of prognostic significance associated with different Leukemic subtypes in
Pakistani population. In: Online Proceedings of AACR (American Association for
Cancer Research) 100TH Annual Meeting—April 18-22, 2009; Colorado, Denver.
71. Zafar Iqbal, Zhao LiJuan, Shahid Baig, Zeba Aziz, Mudassar Iqbal, Ahmad
Khalid, and Tanveer Akhtar. Significance of pretherapeutic genetic testing in patient-
tailored therapy of leukemia as manifested by correlation of pre-Imatinib BCR-ABL
ATP-binding domain mutations and natural Imatinib resistance in CML patients. In:
Online proceedings of AACR (American Association for Cancer Research)
Centennial Conference: Translational Cancer Medicine-- July 20-23, 2008;
Monterey, CA.
Page 15 of 31
72. Iqbal Z, Baig SM, Aziz Z, Shah IH, Khalid M, Iqbal M and Tanveer A
Interferon prior to Imatinib therapy eradicates pre-existing BCR-ABL ATP-binding
domain mutations conferring natural Imatinib resistance and leads to more
sustained/durable molecular response in chronic myeloid leukaemia. In: Proceedings
of, 6th Internal Symposium on Targeted Anti-cancer Therapies (TAT) 2008,
Bethesda USA, p. 39.
73. Iqbal Z., Baig S.M., Aziz Z., Akhtar T. Clinical significance of pre-existing
BCR-ABL gene ATP-binding domain mutations in chronic myeloid leukemia (CML)
patients: implication in prognosis and Imatinib follow-up studies. In: Proceedings of
5th International Symposium on Targeted Anticancer Therapies (TAT Congress),
Amsterdam, March 8-10, 2007, p.59.
74. Iqbal Z. Siddiqui R.T., Qureshi J. A. and Tanveer A and Zeba Aziz. Unraveling
pharmacogenomic basis of primary Imatinib resistance: first report of multiple point
mutations in BCR-ABL gene ATP-binding domain conferring primary Imatinib
resistance in a ph chromosome positive chronic myeloid leukemia (CML) patient. In:
Proceedings of International Conference on Tumor Progression and Therapeutic
resistance, Philadelphia USA, November 8-9, 2004, pp: 56-5.
A. Articles submitted to ISI- indexed journals / Prestigious Conferences:
Page 16 of 31
75. Tashfin A, Iqbal Z., Sabir N, et al. Immunophenotypic characterization of
Pakistani pediatric Acute Lymphoid Leukemia Patients with respect to molecular
subtypes, clinical parameters and treatment outcome. Asian Pac J Cancer Prev.
76. Sabir N, Iqbal Z., Tashfin A, et al. Studies on Immunophenotypic characteristics
of Pakistani adult Acute Lymphoid Leukemia Patients: Association with molecular
subtypes, clinical parameters and treatment outcome. Asian Pac J Cancer Prev.
77. Mahmood Rasool, Zafar Iqbal, Mohammed Hussain Alqahtani, Ishfaq Ahmed
Sheikh et al. Comparative study of alterations in Tri-iodothyronine (T3), Thyroxine
(T4) hormone levels in breast and ovarian cancer in local population. Intl J Oncol.
78. Mahmood Rasool, Zafar Iqbal, Ishfaq Ahmed Sheikh et al. Evaluation of
biochemical markers and malondialdehyde status in patients with thyroid gland
dysfunction receiving interferon therapy. Oncol Reports.
B. GENEBANK (Nucleotide / NCBI) submissions / Citations :
DNA sequences of Hepatitis B Virus (HBV) surface antigen gene (HBsAg) were submitted to
GeneBank (NCBI Core Nucleotide) in 2001-2002. This was a part of M.Phil. research. GeneBank
database sequences’ IDs are:
AY168835-45 (11 sequences)
AF388661-8 (08 sequences)
Clinical / Molecular Diagnostic (MDx) Experience:
Page 17 of 31
1) Founder of Molecular Genetic Pathology Unit and pioneer in introducing molecular
diagnosis of hematological cancers and solid tumors at King Khalid University Hospital,
King Saud University College of Medicine, Riyadh, KSA.
(07-06-2010 to 14-05-2012).
2) Established Cancer Genetics Research & Molecular Diagnostics of Leukemia at
Department of Biotechnology, University of Sargodha, Pakistan (Jun-Nov, 2012).
3) Founder Scientist of Molecular Genetic Testing of Leukemia/Lymphoma and Solid
Tumors at Health Sciences Laboratories, Department of Zoology, University of the
Punjab, Lahore, Pakistan which is currently Pakistan’s largest centre for research,
teaching and molecular diagnostics in Molecular Hematology/Oncology.
(02-2006 to 12-2006 & 1-2009 to 23-12-2012)
4) Pioneer in introducing the molecular hematology/oncology tests and quality control
measures of infectious molecular diagnostics at Ammar Medical Complex, Chughtai
Lahore Laboratories Pakistan.
(12-2009 to 5-2010).
5) Introduced BCR-ABL molecular testing for diagnosis of Chronic Myeloid Leukemia
at Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan.
(04-2009 to 11-2009).
6) Introduced BCR-ABL mutation testing for Chronic Myeloid Leukemia drug-
resistance monitoring and co-established 8-color flow cytometry for diagnosis of
hematological malignancies at Shanghai Institute of Hematology of Rui-Jin Hospital,
Shanghai Jiao-Tong University School of Medicine China (2007-2008).
7) Developed Molecular Testing of Alpha Thalassemia, BRCA1/2 mutation testing in
Breast/ Ovarian cancers, Acute Leukemia and Familial Hypercholesterolemia
Molecular Testing (LDLR gene) for PIBS Diagnostics at Human Molecular Genetics
Page 18 of 31
Laboratory, National Institute for Biotechnology and Genetic Engineering (NIBGE),
Faisalabad, Pakistan.
(5-2002 to 1-2006).
8) Introduced Molecular Testing of Acute Leukemia at Department of Pathology and
Laboratory Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh,
Saudi Arabia.
(12-2006 to 3-2007).
Employment Record:
Assistant Professor (Medical Genetics / Molecular Hematology & Oncology) ,
CAMS, King Saud Bin Abdulaziz University for Health Sciences, King Abdulaziz
Medical City, NGHA, Riyadh, Saudi Arabia (Since November 2012).
Quality Assurance and Academic Accreditation Program Officer (CLSP), CAMS,
King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia (Since
February 2014).
Visiting Professor, “Hematology Oncology and Pharmacogenetic Engg. Sciences
(H.O.P.E.S.) Group, Department of Biotechnology, University of Sargodha, Sargodha,
Pakistan (06/2012 to 23-12-2012).
Visiting Scientist and Principal Investigator, “Hematology Oncology and
Pharmacogenetic Engg. Sciences (H.O.P.E.S.)” Program, Health Sciences/Parasitology
Research Group, Dep’t of Zoology, University of the Punjab, Lahore, Pakistan (1/2009 to
23-12-2012).
Assistant Professor and Group Leader Functional Molecular Cell Biology / Clinical
Hematology & Oncology: Centre for Research in Molecular Medicine (CRiMM) /
Page 19 of 31
Institute of Molecular Biology and Biotechnology (IMBB), the University of Lahore,
Lahore, Pakistan (12/ 2009 to 05-06-2012).
Consultant Molecular Diagnostics / Genetics and In-charge PCR Laboratory,
Ammar Medical Complex and Chughtais Lahore Laboratories (CLL), Lahore. Pakistan
(12-2009 to 05-2010).
Jr. Research Scientist and Group Leader Hemato-oncology: Shaukat Khanum
Memorial Cancer Hospital and Research Centre, Lahore, Pakistan (5/2009 to 11/2009).
Senior Research Officer (SRO): Centre for Excellence in Molecular Biology (CEMB),
University of the Punjab Lahore Pakistan (1/2009 to 5/2009).
Post-doctoral Scientist (Functional Medical Genomics / Hematology and Oncology):
State Key Laboratory of Functional Medical Genomics, Shanghai Institute of
Hematology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, China
(7/2007-12/2008).
Post-doctoral Researcher: “Hematology, Oncology and Pharmacogenetics” at
University of the Punjab, Lahore 54590, Pakistan (3/2007 to 7/2007).
Molecular Hematologist: King Faisal Specialist Hospital and Research Hospital
(KFSH&RC) Riyadh Saudi Arabia (12/2006 to 3/2007).
Researcher: “Hematology, Oncology and Pharmacogenetic-Engineering Sciences
(H.O.P.E.S.), Health Sciences/Parasitology Research Group, Department of Zoology,
University of the Punjab, Lahore 54590, Pakistan” (2/2006 to 11/2006).
Research Officer: Department of Physiology and Cell Biology, University of Health
Sciences, Lahore 54600, Pakistan (4/2006 to 9/2006).
Page 20 of 31
Scientific Officer / Junior Scientist: Cancer Genetic/Human Molecular Genetics
Laboratory, at National Institute for Biotechnology & Genetic Engineering (NIBGE),
Faisalabad, Pakistan from (5/2002 to 1/2006).
Research officer: H.O.P.E.S., Dep’t. of Zoology, University of the Punjab, Lahore,
Pakistan (3/2001 to 5/2002).
Research Scholar (Molecular Biomedical sciences): Center of Excellence in Molecular
Biology (CEMB), Punjab University Lahore Pakistan (3/1999-2001). At the completion
of research at CEMB, Degree of Master of Philosophy (MPhil) in Molecular Biology was
awarded.
Molecular/Genetic Techniques Hands-on Training:
DNA/RNA/Protein extraction using Robotic arms (MagNApure, Roche), Kits and
Manual methods (TriZol and Phenol-Chloroform Extraction methods).
Real Time Q-PCR: Application in Gene Expression Profiling, Anti-cancer therapy
selection & follow-up, Genetic studies (Mutation detection, SNPs etc.).
M.R.D. (minimal residual disease) monitoring in Leukemia using RTQ-PCR.
Multiplex RT-PCR & ARMS-PCR (mutation/SNP detection) for Cancer genetic testing.
DNA sequencing using ABI310 and ABI 3500 Genetic Analyzers.
Cancer F.I.S.H. (Fluorescent in situ Hybridization) using CytoVision 7.2 system.
Cancer Microarray (cytoband) analysis using Affymetrix microarray system.
Sequenom (DNA Mass Spectrometry) for Cancer Gene mutations and SNP typing.
Intensive use of bioinformatics, biostatistics and Databases for DNA/RNA/Protein
analysis e.g. designing primers/probes, DNA sequencing, experimental design etc.
Recombinant DNA Techniques: Cloning, transformation, Restriction Analysis, etc.
Page 21 of 31
Confocal Microscopy, Fluorescent Microscopy and bright- field microscopy.
Flow Cytometry, Fluorescent assisted cell sorting and Immunocytochemistry.
Western blotting.
Cell culturing (Human, Mice, bacteria); viral culturing; Chromosomal analysis etc.
Lentiviral/Liposomal gene transfer to mouse and Human tissues; mice experiments.
Eleven year experience of molecular diagnostics (MDx) as well as writing, planning,
execution, reporting, publishing and laboratory management of research / diagnostic /
clinical investigation projects in R&D sector and Hospitals as well as teaching/co-
supervising BS/MS/Phil students as well as PhD and post-PhD fellows at University level.
Research Funding:
1. “Studies on frequencies and disease progression potential of candidate
Lymphoid and Myeloid lineage gene mutations in Chronic Myeloid Leukemia
Lymphoid and Myeloid blast Crisis CD34+ stem cells” by KACST (Project # 14-
MED487-22), SR. 2 million (Co-investigator).
2. “Highthoughput cytogenetic and molecular analysis to reveal novel
abnormalities associated with transformation to advanced disease and tyrosine
kinase inhibitor resistance in Chronic Myeloid Leukemia” , by King Abdulaziz
City for Science and Technology (Project # ARP-35-200, funded amount Saudi Riyal
2 million), at National Guard Health Affairs, Riyadh, Saudi Arabia (Principal
Investigator).
Page 22 of 31
3. “Studies on frequencies and disease progression potential of candidate
Lymphoid and Myeloid lineage gene mutations in Chronic Myeloid Leukemia
Lymphoid and Myeloid blast Crisis CD34+ stem cells” by King Abdulaziz City for
Science and Technology (Project # ARP-35-200, funded amount Saudi Riyal 2
million equivalent to Pk Rs. 54 million, 2015-2017), at National Guard Health
Affairs, Riyadh, Saudi Arabia (Co- Investigator).
4. “BCR-ABL mutations associated with resistance to imatinib in Chronic Myeloid
Leukemia patients”, by Higher Education Commission Pakistan (Project #
20-1370/R&D/09, funding amount PKRs 4.2 million, 2011-13), at Punjab University
Lahore Pakistan (Co-Investigator).
5. “Molecular genetic studies of Leukemia: Implication in differential diagnosis,
prognosis and anti-leukemia therapy monitoring”, by Shaukat Khanum Memorial
Cancer Hospital & Research Centre (SKMCH&RC) Lahore Pakistan (Funded amount
PKRs 3.0 million, 2009), at SKMCH&RC, Lahore, Pakistan (Principal Investigator).
6. Post-doctoral Fellowship Project “Functional characterization of NUP98-IQCG
fusion oncogene in acute leukemia”, funded by Shanghai Education Commission
Shanghai China (2007-2008), at Shanghai Institute of Hematology, Shanghai Jiao-
Tong University School of Medicine, Shanghai, China (Postdoctoral Scientist).
7. “Y-chromosome microdeletions associated with male infertility in Pakistan”, funded
by Pakistan Science Foundation (Funded amount 1.0 million, 2004-6), at National
Page 23 of 31
Institute for Biotechnology and Genetic Engineering (NIBGE), Faisalabad, Pakistan
(Co-Investigator).
8. Project “Low density lipoprotein receptor gene (LDLR) mutations associated with
familial hypercholesterolemia”, funded by Pakistan Science Foundation (Funded
amount 1.0 million, 2006-8), at NIBGE, Faisalabad, Pakistan (Co-investigator).
MS/MPhil and PhD Research Co-supervision:
Completed / Thesis defense:
PhD supervised at University of the Punjab Lahore, 2010-2015.
1. PCR-based analysis of prognostically important fusion oncogenes in Pakistani
pediatric acute lymphoblastic leukemia patients and their association with disease
biology and treatment outcome (Tashfeen Awan, Hematology/ Genetics) 2013.
2. PCR-based analysis of prognostically important fusion oncogenes in Pakistani
pediatric acute lymphoblastic leukemia patients and their association with disease
biology and treatment outcome (Noreen Sabir, Hematology/ Genetics) 2014.
3. BCR-ABL mutations associated with Imatinib resistance and advanced disease phases
in Chronic Myeloid Leukemia (Afia M. Akram, Hematology /Genetics) 2014.
4. Molecular Genetic studies of Acute Myeloid Leukemia in Pakistan (Sana Shahbaz,
Hematology/Genetics) 2015; Thesis submitted 2015.
Page 24 of 31
MS/MPhil (University of The Punjab, Lahore) (Cancer Pharmaco-genomics) 4
MPhil (University of Health Sciences, Lahore) (Cancer Genetics) 1
MPhil (NIBGE Faisalabad) MS/MPhil (Human Molecular Genetics) 2
In Process (University of the Punjab Lahore Pakistan):
One Post-doctoral Fellow (Molecular Basis of Drug Resistance in Leukemia).
7 PhDs (Molecular Genetics of Hematological Neoplasms and Breast Cancer).
One MS/MPhil (Genetics of Nilotinib resistance in Ph+ Leukemia).
Research Awards:
1. Wallace H. Coulter Foundation-ASH (American Society of Hematology) Abstract
Achievement Award, ASH Annual Meeting, Dec. 2014, San Francisco, CA, USA.
2. ASH Abstract Achievement Award, ASH Annual Meeting, Dec. 2013, New Orleans, LA.
3. European Hematology Association Travel Grant 2013: Annual Meeting, Sweden.
4. ASH (American Society of Hematology) Travel Award, ASH Annual Meeting, Dec. 2010.
5. Susan G. Komen / AACR Scholar-in-Training Award 2010: American Association for
Cancer Research (AACR) Award, AACR Special Conference “Advances in Cancer Research-
From Laboratory to Clinic” at Amman, Jordan, from March 07-10, 2010.
6. AACR / ITO EN Scholar-in-Training Award 2009: AACR 100TH Annual Meeting—April
18-22, 2009; Colorado, Denver.
7. Shanghai Education Commission Fellowship (Clinical Hematology): Research/clinical
training at Shanghai Jiao-Tong University College of Medicine China in the field of Functional
Medical Genomics / Clinical Hematology.
Page 25 of 31
8. SIES Award 2006: Italian Society of Experimental Hematology (SIES) in IX Congress of this
society (September 2006); research paper “Role of Pre-existing BCR-ABL gene ATP-binding
domain mutations in outcome of Gleevec therapy in CML”.
9.PSF Travel Award: Pakistan Science Foundation (PSF) Travel award to participate in VIII
Congress of Italian Society of Experimental Hematology (September 2006).
10. Best Cancer Researcher Award: Awarded by Society of Clinical Oncology Pakistani
(SCOP) on occasion of their 10th National and 1st International cancer conference (18th-21st
December 2003), for best cancer research article in the field of Leukemia.
11. Educational Scholarships : Educational Merit Scholarships by University &
Educational Boards in Ph.D., M.Phil., Grade-12, Grade-10 and Grade-5 classes (1985-2002).
University / Medical College Teaching and Academic Experience:
1. Curriculum design and teaching a course on “Molecular Pathology Course for Pathology
Residents / Fellows / Consultants ” at Department of Pathology, Kind Abdulaziz Medical
City, National Guard Health Affairs, Riyadh, Saudi Arabia (2013-2014).
2. Curriculum design and Teaching subjects of “Medical Genetics, Molecular Diagnostics
and Immunology” at College of Applied Medical Sciences and College of Medicine, KSA-
UHS, National Guard Health Affairs, Riyadh, Saudi Arabia (Since November 2012).
3. Taught the subjects of “Molecular Genetics and Hematology/Oncology” to “Medical
Residents and Fellows of KSU-Fellowship Program in Hematology / Pathology” at
Department of Pathology, King Saud University College of Medicine, King Khalid
University Hospital, Riyadh (Since 07-06-2010).
4. Developed the CURRICULA for MS/PhD program in Molecular Genetic Pathology at King
Saud University College of Medicine, Riyadh, Saudi Arabia.
Page 26 of 31
5. Developed the 5-year program for research, teaching and clinical services at Molecular
Genetic Pathology Unit, King Saud University College of Medicine, King Khalid University
Hospital, Riyadh, Saudi Arabia.
6. Taught the subjects of “Advanced Molecular Biology, Cancer Biology, Molecular
Hematology, Leukemia Genetics, Molecular Pathology and Advanced Experimental
Biology” to “BS, MS and PhD students” , as Assistant Professor at Centre for Research in
Molecular Medicine (CRiMM), Institute of Molecular Biology and Biotechnology (IMBB),
The University of Lahore, Lahore, Pakistan.
7. Developed the curricula for above-mentioned subjects (12-2009 to 06-2010).
8. A: Taught the subjects of “Advanced Molecular Biology, Human Cytogenetics,
Leukemia Genetics, Cancer Biology, Molecular Hematology and Molecular Pathology”
to “MS and PhD students” as Visiting Scientist at Faculty of Biological Sciences, Dep’t of
Zoology, University of the Punjab, Lahore, Pakistan. B: Developed the
curricula for the mentioned subjects (1-2009 to 06-2010).
9. Taught the subjects of “Human Molecular Genetics, Molecular Hematology and Cancer
Genetics” to “MS /PhD students” as Scientific Officer at Human Molecular Genetics
Group , Health Biotechnology Division, National Institute for Biotechnology & Genetic
Engineering (NIBGE), Faisalabad, Pakistan from (5/2002 to 1/2006).
10. Taught the subjects of “Molecular Parasitology and Vector Biology” to “BS and MS
students” as Research Officer at Faculty of Biological Sciences, Dep’t of Zoology,
University of the Punjab, Lahore, Pakistan (3-2001 to 05-2002).
Membership of International Research Bodies/Agencies:
Page 27 of 31
I. American Association for Cancer Research (AACR) 2008-2011
II. European Hematology Association (EHA) 2012-2014
III. American Society of Clinical Oncology (ASCO) 2012
IV. American Society for Pediatric Hematology and Oncology (ASPHO) 2007-2010
V. Saudi Society for Bone Marrow Transplantation (SSBMT) 2012-continued
VI. National Academy of Young Scientists (NAYU), Pakistan. 2012-continued
VII. Fellow, Shanghai Institute of Hematology (SIH), China. 2007-2008
VIII. President Pakistan Society for Molecular and Clinical Hematology (A.S.H. Partner)
Congress and Symposia Attended:
1. American Society of Hematology (ASH) Annual Meeting, Dec. 2014, San Francisco, CA.
2. European Hematology Association (EHA), Annual Meeting June 2014 Milan Italy.
3. ASH-Highlights Asia Meeting, 29-30th Mar 2014, Singapore.
4. ASH Annual Meeting, Dec. 2013, New Orleans, LA.
5. Second Saudi CML Summit 2011. Hilton Hotel Jeddah, Saudi Arabia (Jan 27, 2011).
6. Saudi Hematology Association Conference, Riyadh Saudi Arabia (Sep 29, 2010).
7. American Association for Cancer Research (AACR) Special Conference “Advances in
Cancer Research-From Laboratory to Clinic” at Amman, Jordan, (March 07-10, 2010).
8. 12th National Haematology Conference, Lahore, Pakistan (Feb 9-16, 2010).
9. AACR 100th Annual Meeting, Denver, .Colorado. (April 18-22, 2009)
10. 21st Century Challenges in Hematology” (20th Anniversary of Shanghai Institute of
Hematology, Rui-Jin Hospital), Jiao-Tong University School of Medicine, China (Oct 2008).
Page 28 of 31
11. 5th International Symposium on Targeted Anticancer Therapies (TAT Congress),
Amsterdam, Netherlands (March 8-10, 2007).
12. IX Congress, Italian Society of Experimental Hematology, Milano, Italy (September 2006).
13. International Conference on Tumor Progression and Therapeutic resistance, Philadelphia
USA (November 8-9, 2004).
14. 10th National/1st International cancer conference, Pakistani Society of Clinical Oncology,
Pearl continental Hotel, Peshawar, Pakistan (18th-21st December 2003).
15. Symposium on "Molecular Biology Approach to Diagnostics & Prevention of Genetic
Diseases, CEMB, Punjab University, Lahore, Pakistan (Feb.4, 2000).
16. 17th Pakistan Congress of Zoology University of the Sind, Karachi, Pakistan (4/1997).
17. 18th Pakistan Congress of Zoology University of the Punjab, Lahore, Pakistan (4/1998).
References:
1) Dr Rizwan C. Naeem, MD, PhD, FACMG, DABMG
Professor of Pathology & Director Molecular Pathology
Director ABMG Lab Genetics Fellowship Program
Albert Einstein College of Medicine and Montefiore Medical Centre
Bronx, NY, USA.
Phone: 718-405-8101; Fax: 718-931-3637
Email: [email protected]
Page 29 of 31
2) Professor Dr Masood A. Shammas, PhD
Director, Translational Genomic Instability Program
Jeromy Lipper Myeloma Center, Harvard (Dana Farber) Cancer Institute
Research Health Scientist, VA Boston Health Care System
Harvard Medical School at VAMC
Harvard University, West Roxbury, MA 02132
Phone: 1-857-203-6172 Office. Fax: 1-781-507-1075 Cell
E-mail: [email protected]
3) Professor Walid E. Khalbuss, MD PhD
Dept. of Pathology, University of Pittsburgh, Pittsburgh, PA, USA
5230 Centre Ave, Pittsburgh, PA 15232.
Director, GE Healthcare at National Guard Health Affairs, Riyadh, Saudi Arabia.
Phone: (412) 623-1109, Fax: (412) 682-6450
E-mail: [email protected] ; [email protected]
4) Dr Muhammad Faiyaz-Ul-Haque, MPhil PhD FRCPath
Professor, Consultant & Director, Molecular Pathology Unit
Department of Pathology and Laboratory Medicine
College of Medicine and King Khalid University HospitalPage 30 of 31
King Saud University, Riyadh 11461, Pakistan.
Phone: +966-1-469-9377
E-mail: [email protected] , [email protected]
5) Dr Muhammad Azhar Chishti, PhD
Scientist, University of Toronto
4424 Marshdale Court, Mississauga ONT L5M 4G1, Canada.
Phone: +1-905-593-8835
E-mail: [email protected]
6) Professor Tanveer Akhtar, PhD Post-doctorate (Manitoba)
Director, Higher Education Project in Hematology, Oncology and
Pharmacogenetic Engineering Sciences (HOPES), Health Sciences Laboratories,
Faculty of Biological Sciences, Department of Zoology, University of the Punjab,
Lahore 54590, Pakistan.
Phone: +92-321-4257861, +92-42-9923124
E-mail: [email protected]
7) Professor Ahmad M Khalid, PhD
Director, Department of Biotechnology
University of Sargodha, Pakistan.
Phone: +92-300-8651900
E-mail: [email protected]
Page 31 of 31